ACCESSIBILITY

24/7

Headlines

22:23

Intel shares fall back to April levels after losing over half their value in five weeks

21:50

Intel’s Israeli workers fear another downturn after stock collapse and deadly factory blast

21:37

Ground Up Ventures appoints Navot Volk as General Partner

21:22

After years of delays, IDF prepares to deploy Elbit’s new Ro'em artillery systems

Buzz

Most popular

Daily

Weekly

From six-person startups to a $6.3 billion take-private: October's extraordinary month for Israeli tech exits

ServiceNow CEO says acquired Israeli startup Sweep helps it switch CRM customers in weeks, not years

Perion to be acquired by India’s Affle for $420 million, marking a steep fall for a once-billion-dollar Israeli company

Israeli startup Coldi is deploying AI agents to take over the cold call

Stealth Israeli cyber startup valued at over $1.5 billion recruits former 8200 chief

More news

Kåre Schultz

9 stories about Kåre Schultz

Teva Announces Restructuring, Ousts Second in Command

27.11.17|Golan Hazani

The troubled Israeli drugmaker has combined its generic and specialty drug divisions, effective immediately

Israeli Parliamentarians to Push Against Teva Layoffs in the Country

26.11.17|Dror Reich and Maayan Manela

Shelly Yachimovich, a member of the Israeli parliament representing the Israeli Labor Party, said she intends to call an emergency hearing of the Israeli parliament’s state control committee on the issue. The planned layoffs are a result of the company’s management failures, she added

Troubled Drugmaker Teva to Axe over 4,000 Jobs

23.11.17|Golan Hazani

Less than a month after stepping in as CEO, Kåre Schultz starts tightening the belt. The company is expected to oust Chief Scientific Officer Michael Hayden

Generic Dependence Threatens Teva’s Ability to Haul Debt Load

05.11.17|Dror Reich and Lilach Baumer

Teva’s stock price dropped 18.7% last week after the company lowered its annual forecasts. On Friday, S&P changed the company’s outlook to negative

With New CEO in Seat, Teva Lowers Outlook

02.11.17|Lilach Baumer and Dror Reich

Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17|Lilach Baumer

The generic drugmaker shed 67% of its market price over the last 12 months

New Teva CEO Kåre Schultz to Relocate to Israel

17.10.17|Golan Hazani

Mr. Schultz, who led Copenhagen-based H. Lundbeck A/S since 2015, will come to Israel and assume his new position by the end of the month

The Ten Challenges Facing Teva's New CEO

12.09.17|Sophie Shulman

Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld

The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated